Cargando…

Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma

IMPORTANCE: Administration of atezolizumab could be immunogenic and induce undesirable antidrug antibody (ADA) responses. This may interfere with atezolizumab-mediated actions, affecting drug clearance and serum concentration or inducing antibody neutralization. OBJECTIVE: To determine the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Chan, Yang, Hannah, Kim, Ilhwan, Kang, Beodeul, Kim, Hyeyeong, Kim, Hyunho, Lee, Won Suk, Jung, Sanghoon, Lim, Ho Yeong, Cheon, Jaekyung, Chon, Hong Jae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585463/ https://www.ncbi.nlm.nih.gov/pubmed/36264560 http://dx.doi.org/10.1001/jamaoncol.2022.4733

Ejemplares similares

Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
por: Cheon, Jaekyung, et al.
Publicado: (2023)

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
por: Yang, Hannah, et al.
Publicado: (2023)

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
por: Chon, Young Eun, et al.
Publicado: (2022)

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
por: Kim, Beom Kyung, et al.
Publicado: (2022)

The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma
por: Kim, Han Sang, et al.
Publicado: (2022)

High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma
por: Kim, Youngun, et al.
Publicado: (2023)

Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro
por: Hammer, Christian, et al.
Publicado: (2022)

High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma
por: Sang, Yun Beom, et al.
Publicado: (2022)

High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer
por: Park, Hyung Soon, et al.
Publicado: (2021)

The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate
por: Mojtahed Poor, Sorwe, et al.
Publicado: (2023)

STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer
por: Lee, Seung Joon, et al.
Publicado: (2021)

Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision
por: Adair, Patrick R., et al.
Publicado: (2017)

Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies
por: Bitoun, Samuel, et al.
Publicado: (2023)

Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway
por: Kim, Jeong Hun, et al.
Publicado: (2021)

Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection
por: Eser, Alexander, et al.
Publicado: (2020)

ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer
por: Lee, Sung Hwan, et al.
Publicado: (2023)

Therapeutic Protein PEPylation: The Helix of Nonfouling Synthetic Polypeptides Minimizes Antidrug Antibody Generation
por: Hou, Yingqin, et al.
Publicado: (2019)

Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents
por: Reinisch, Walter, et al.
Publicado: (2017)

Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases
por: Benucci, Maurizio, et al.
Publicado: (2018)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Kim, Tae Hyun, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab
por: Ehrenpreis, Eli D.
Publicado: (2017)

Impact of glycoengineering and antidrug antibodies on the anticancer activity of a plant‐made lectin‐Fc fusion protein
por: Dent, Matthew, et al.
Publicado: (2022)

Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove
por: Tsakok, Teresa, et al.
Publicado: (2023)

Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis
por: Cheon, Jaekyung, et al.
Publicado: (2021)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

A machine learning approach for identifying variables associated with risk of developing neutralizing antidrug antibodies to factor VIII
por: Rawal, Atul, et al.
Publicado: (2023)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
por: Wu, Yue Linda, et al.
Publicado: (2022)

Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma
por: Han, Ji Won, et al.
Publicado: (2023)

Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins
por: Benucci, Maurizio, et al.
Publicado: (2015)

Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study
por: Kim, Ji Hoon, et al.
Publicado: (2023)

Antidrug resistance in the Indian ambient waters of Ahmedabad during the COVID-19 pandemic
por: Kumar, Manish, et al.
Publicado: (2021)

Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis
por: Bang, Yeong Hak, et al.
Publicado: (2022)

A case of successful surgical treatment for peritoneal seeding of hepatocellular carcinoma after radiotherapy and atezolizumab plus bevacizumab combination treatment
por: Cho, Yuri, et al.
Publicado: (2023)

Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients
por: Lim, Sun Min, et al.
Publicado: (2016)

A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testing
por: Liao, Kai H., et al.
Publicado: (2020)

Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice
por: Herszényi, Krisztina, et al.
Publicado: (2019)

Neutralizing antidrug antibody to emicizumab in patients with severe hemophilia A: Case report of a first noninhibitor patient and review of the literature
por: Kizilocak, Hande, et al.
Publicado: (2023)

Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer
por: Lee, Yu Seong, et al.
Publicado: (2020)

Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
por: Kim, Yong Tae, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_24120m9qunlkrt8k3101s4ljr7